in

Booster Covid Shots Aren’t Needed, Say 18 Top Epidemiologists, In THE LANCET

The statements, views and opinions expressed in this column are solely those of the author and do not necessarily represent those of this site. This site does not give financial, investment or medical advice.

These excerpts are posted by Eric Zuesse

“A consistent finding is that vaccine efficacy is substantially greater against severe disease than against any infection; in addition, vaccination appears to be substantially protective against severe disease from all the main viral variants. Although the efficacy of most vaccines against symptomatic disease is somewhat less for the delta variant than for the alpha variant, there is still high vaccine efficacy against both symptomatic and severe disease due to the delta variant.”

THE ARTICLE:

“Considerations in boosting COVID-19 vaccine immune responses”

https://www.thelancet.com/pb-assets/Lancet/pdfs/S0140673621020468.pdf

Viewpointwww.thelancet.com Published online September 13, 2021

FROM:

Office of Vaccines Research and Review, Food and Drug Administration, Silver Spring, MD, USA (P R Krause MD, M F Gruber PhD); Department of Biostatistics, University of Washington, Seattle, WA, USA (Prof T R Fleming PhD); Nuffield Department of Population Health, University of Oxford, Oxford, UK (Prof R Peto FRS); Department of Biostatistics, University of Florida, Gainesville, FL, USA (Prof I M Longini PhD); University of the West Indies, Mona, Jamaica (Prof J P Figueroa PhD); Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK (Prof J A C Sterne PhD, Prof J P T Higgins PhD); Universidad Nacional Autónoma de México, DF, Mexico (A Cravioto PhD); Wits Reproductive Health and HIV Institute, Johannesburg, South Africa (Prof H Rees MD); Centre of Research in Epidemiology and Statistics (CRESS), Université de Paris, Paris, France (Prof I Boutron PhD); MRC Population Health Research Unit, University of Oxford, Oxford, UK (Prof H Pan PhD); The INCLEN Trust International, New Delhi, India (Prof N Arora MD); World Health Organization, Geneva, Switzerland (F Kazi PhD, R Gaspar PhD, S Swaminathan MD, M J Ryan MD, A-M Henao-Restrepo MD) Correspondence to: Dr Philip R Krause Office of Vaccines Research and Review, Food and Drug Administration, Silver Spring, MD 20993, USA philip.krause@fda.hhs.gov or Dr Ana-Maria Henao-Restrepo World Health Organization, Geneva 1211, Switzerland henaorestropa@who.int

THE ARTICLE’S OPENING:

A new wave of COVID-19 cases caused by the highly transmissible delta variant is exacerbating the worldwide public health crisis, and has led to consideration of the potential need for, and optimal timing of, booster doses for vaccinated populations.1 Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society. COVID-19 vaccines continue to be eective against severe disease, including that caused by the delta variant. Most of the observational studies on which this conclusion is based are, however, preliminary and dicult to interpret precisely due to potential confounding and selective reporting. Careful and public scrutiny of the evolving data will be needed to assure that decisions about boosting are informed by reliable science more than by politics. Even if boosting were eventually shown to decrease the medium-term risk of serious disease, current vaccine supplies could save more lives if used in previously unvaccinated populations than if used as boosters in vaccinated populations.

Boosting could be appropriate for some individuals in whom the primary vaccination, defined here as the original one-dose or two-dose series of each vaccine, might not have induced adequate protection — eg, recipients of vaccines with low ecacy or those who are immunocompromised2 (although people who did not respond robustly to the primary vaccination might also not respond well to a booster). It is not known whether such immunocompromised individuals would receive more benefit from an additional dose of the same vaccine or of a dierent vaccine that might complement the primary immune response.

Boosting might ultimately be needed in the general population because of waning immunity to the primary vaccination or because variants expressing new antigens have evolved to the point at which immune responses to the original vaccine antigens no longer protect adequately against currently circulating viruses.

Although the benefits of primary COVID-19 vaccination clearly outweigh the risks, there could be risks if boosters are widely introduced too soon, or too frequently, especially with vaccines that can have immune-mediated side-eects (such as myocarditis, which is more common after the second dose of some mRNA vaccines,3 or Guillain-Barre syndrome, which has been associated with adenovirus-vectored COVID-19 vaccines4). If unnecessary boosting causes significant adverse reactions, there could be implications for vaccine acceptance that go beyondCOVID-19 vaccines. Thus, widespread boosting should be undertaken only if there is clear evidence that it is appropriate. Findings from randomised trials have reliably shown the high initial ecacy of several vaccines, and, less reliably, observational studies have attempted to assess the eects on particular variants or the durability of vaccine ecacy, or both. The appendix identifies and describes the formal and informal reports from these studies. Some of this literature involves peer-reviewed publications; however, some does not, and it is likely that some details are importantly wrong and that there has been unduly selective emphasis on particular results.Together, however, these reports provide a partial but useful snapshot of the changing situation, and some clear findings emerge. The figure summarises the reports that estimated vaccine ecacy separately for severe disease (variously defined) and for any confirmed SARS-CoV-2 infection, plotting one against the other. A consistent finding is that vaccine ecacy is substantially greater against severe disease than against any [covid-19] infection; in addition, vaccination appears to be substantially protective against severe disease from all the main viral variants. Although the ecacy of most vaccines against symptomatic disease is somewhat less for the delta variant than for the alpha variant, there is still high vaccine ecacy against both symptomatic and severe disease due to the delta variant.

Current evidence does not, therefore, appear to show a need for boosting in the general population, in which ecacy against severe disease remains high. Even if humoral immunity appears to wane, reductions in neutralising antibody titre do not necessarily predict reductions in vaccine ecacy over time, and reductions in vaccine ecacy against mild disease do not necessarily predict reductions in the (typically higher) ecacy against severe disease. This eect could be because protection against severe disease is mediated not only by antibody responses, which might be relatively short lived for some vaccines, but also by memory responses and cell-mediated immunity, which are generally longer lived.5 The ability of vaccines that present the antigens of earlier phases of the pandemic (rather than variant-specific antigens) to elicit humoral immune responses against currently circulating variants6,7 indicates that these variants have not yet evolved to the point at which they are likely to escape the memory immune responses induced by those vaccines. …

Report

The statements, views and opinions expressed in this column are solely those of the author and do not necessarily represent those of this site. This site does not give financial, investment or medical advice.

What do you think?

Subscribe
Notify of
guest
6 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Helga I. Fellay
Helga I. Fellay
September 13, 2021
Rate this article :
     

Booster shots do only damage, no good. They are actually more dangerous than the virus itself, especially for people with healthy immune systems because the cause the virus to mutate (i.e. Delta, Mu), which are more dangerous than the original virus, requiring additional booster shots, which will result in yet more mutations to more dangerous viruses. “Massachusetts has had 5,166 breakthrough cases of COVID-19 as of July 17, 2021, with 716 of the cases occurring in just week, according to the state Department of Public Health (DPH). Between July 10, 2021, and July 16, the DPH reported 1,649 new positive… Read more »

Last edited 1 month ago by Helga I. Fellay
Helga I. Fellay
Helga I. Fellay
Reply to  Eric Zuesse
September 14, 2021

showing your true colors, like a true MSM rep. The NWO has officially declared him to be their #1 Enemy. That means they fear him more than anyone else. But we also know that what they fear most, more than they fear any man, is the truth. Maybe he’ll end up sharing a cell with Julian Assange some day, another dangerous man who dared reveal the truth. But I am getting carried away…. Btw – why do you demand that access to the scientific literature must be “facilitated”? Scientific literature can easily be accessed via Google, or whatever browser you… Read more »

Helga I. Fellay
Helga I. Fellay
Reply to  Eric Zuesse
September 14, 2021

I think I have figured out why Dr. Mercola doesn’t “facilitate” access to the scientific literature – it is that he is also trying to make a living like everyone else and finds that if you are really interested, you are encouraged to buy his bestseller book: “My latest book, “The Truth About COVID-19,” is an instant best seller. With hundreds of thousands of copies sold, it has a nearly perfect 5-star rating so grab your copy of the #1 best-selling book on Amazon today before Biden bans it.” This means that his findings ARE in fact verifiable. If they hadn’t been verified, the… Read more »

“…The Unmentionable Life Of Arnold Spencer Leese” — reviewed

Neocons Undermine Biden on China Ties. Brief Media on Taiwan Talks, Beijing Threatens War